For pharmaceutical and biopharma companies, building quality into your products from an early stage is a key factor in regulatory approval and market success. Design of Experiments (DOE) is an essential tool for achieving both regulatory compliance and faster time to market.
[This blog was a favorite last year, so we thought you'd like to see it again. Send us your comments or questions!]
Whether you work in engineering, R&D, or a science lab, understanding the basics of experimental design can help you achieve more statistically optimal results from your experiments or improve your output quality.
In the midst of a global COVID-19 pandemic, a top priority for many pharma and biopharma companies is to get a vaccine developed, produced and delivered to the public as quickly as possible. Ushering a vaccine through rigorous testing protocols and regulatory approvals is not an easy (or quick) effort, but incorporating advanced data analytics could help accelerate the process. Data analytics has proven effective in speeding vaccine development both by enabling more efficient Design of Experiments (DOE) and by creating rapid-scale production rollout processes.
A new diagnostic method for detecting a rare kidney stone disease has recently been developed at the University of Iceland. Instead of using urine microscopy, which has certain disadvantages, the diagnostic method is based on mass spectrometry of plasma samples. Preliminary clinical data shows very promising results both in terms of detecting the disease and therapeutic drug monitoring. Design of Experiments (DOE) was used as a chemometric approach to optimize the assay. Below is a summary of the assay development and optimization.
Biosimilars are an exciting route to increasing access to the highly effective therapy made possible by biologics, but ensuring a biosimilar meets the critical quality attributes (CQA) of the original biologic is a major challenge. Optimizing production at full scale is impractical, which makes a quality by design (QbD) approach using a reliable scale down model of the process an attractive alternative. A process development team at Zhejiang Hisun Pharmaceuticals, Taizhou, China, therefore developed a scaled down model of the cell culture process used to produce the biosimilar adalimumab. They qualified the model using multivariate data analysis (SIMCA), and explored the design space for key process attributes (KPA) and CQAs using MODDE.
A challenge for the regenerative medicine industry is to develop cell culture processes that can be scaled up for high volume production. Finding a better way to scale up commonly used research cells like HEK293T (used for protein expression and the production of recombinant retroviruses or lentiviral vectors) would be beneficial for biologists in many fields of medicine. Dr. Franziska Bollmann, virus scientist at Sartorius Stedim Biotech in Germany, recently conducted two experiments to find out if micro bioreactor systems can help facilitate the transition from the traditional shake flask process to a more improved method optimizing process control.
One key to reducing R&D costs in the biopharmaceutical market is streamlining and speeding up process data flow for Design of Experiments (DOE). Now, a direct integration of Genedata Bioprocess® platform and Umetrics Suite MODDE® software enables seamless data flow and facilitates the design, execution and evaluation of experiments in large-molecule process development.
What’s the secret formula for creating long-lasting bubbles? Is expert knowledge of liquid dynamics needed to optimize the mixture design and develop the best bubble solution? Or can we use design of experiments (DOE) and data analytics to draw conclusions? Let’s a take a look at a fun example of how DOE can be used to optimize a mixture design in order to achieve our goal: create long-lasting bubbles.
Pressure to cut development costs and lower regulatory barriers while assuring product quality has stimulated the pharmaceutical industry to apply Quality by Design (QbD) to manage risk and gain process and product understanding. As a result, QbD is being widely promoted by regulatory authorities such as the Food and Drug Administration, and the International Conference on Harmonization.
When it comes to continuous quality improvement and removing defects from a process, Six Sigma continues to be the gold standard in manufacturing and process management. This structured, data-driven methodology for discovering problems relies on rigorous analysis of production and process data. For many companies, engaging in a Six Sigma process can be time consuming or even a bit daunting.
You may have heard the term Six Sigma used in conjunction with lean manufacturing, a Kaizen approach or continuous quality improvement. Perhaps you thought Six Sigma only applied to large-scale business operations, or that newer philosophies had overtaken Six Sigma as the most updated approach to quality management? But if you're looking for a way to improve your production processes or solve a problem you’re having with quality, Six Sigma might be the answer. Are you and your team familiar with these concepts? Here's an overview.